RNAi of cat-2, a putative tyrosine hydroxylase, increases alpha synuclein aggregation and associated effects in transgenic C. elegans

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 4, 2012, Pages 387-394

  Kaur, Supinder ^a   Sammi, Shreesh Raj ^a   Jadiya, Pooja ^a   Nazir, Aamir ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

C. elegans; Cat 2; Neurodegeneration; Parkinson's disease; RNAi; Tyrosine hydroxylase

Indexed keywords

ACETYLCHOLINE; ALPHA SYNUCLEIN; CARRIER PROTEIN; CAT 2 PROTEIN; CHOLINERGIC TRANSPORTER; DOPAMINE; DOPAMINE TRANSPORTER; GREEN FLUORESCENT PROTEIN; LIPID; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; EMBRYO; GENE SILENCING; LIPID COMPOSITION; LOCOMOTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TRANSGENIC ORGANISM;

EID: 84862570770     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800792811     Document Type: Article

References (46)

1. Nagatsu, T.; Levitt, M.; Udenfriend, S. Tyrosine Hydroxyls. The initial step in norepinephrine biosynthesis. J. Biol. Chem., 1964, 239, 2910-2917.
2. Møller, L.B.; Romstad, A.; Paulsen, M.; Hougaard, P.; Ormazabal, A.; Pineda, M.; Blau, N.; Güttler, F.; Artuch, R. Pre- and postnatal diagnosis of tyrosine hydroxyls deficiency. Prenat. Diagn., 2005, 25(8), 671-675.
3. Samii, A.; Nutt, J.G.; Ransom, B.R. Parkinson's disease. Lancet, 2004, 363(9423), 1783-1793.
4. Kim, S.S.; Moon, K.R.; Choi, H.J. Interference of alpha-synuclein with cAMP/PKA-dependent CREB signaling for tyrosine hydroxylase gene expression in SK-N-BE(2) C cells. Arch. Pharm. Res., 2011, 34(5), 837-845.
5. Yu, S.; Zuo, X.; Li, Y.; Zhang, C.; Zhou, M.; Zhang, Y.A.; Uéda, K.; Chan, P. Inhibition of tyrosine hydroxylase expression in alphasynuclein- transfected dopaminergic neuronal cells. Neurosci. Lett., 2004, 367(1), 34-39.
6. Furukawa, Y.; Graf, W.D.; Wong, H.; Shimadzu, M.; Kish, S.J. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology, 2001, 56(2), 260-263.
7. Hertz, J.M.; Ostergaard, K.; Juncker, I.; Pedersen, S.; Romstad, A.; Møller, L.B.; Güttler, F.; Dupont, E. Low frequency of Parkin, Tyrosine Hydroxyls, and GTP Cyclohydrolase I gene mutations in a Danish population of early-onset Parkinson's Disease. Eur. J. Neurol., 2006, 13(4), 385-390.
8. Bademci, G.; Edwards, T.L.; Torres, A.L.; Scott, W.K.; Züchner, S.; Martin E.R.; Vance, J.M.; Wang, L. A rare novel deletion of the tyrosine hydroxylase gene in Parkinson disease. Hum. Mutat., 2010, 31(10), E1767-1771.
9. Walter, M.F.; Zeineh, L.L.; Black, B.C.; McIvor, W.E.; Wright, T.R.; Biessmann, H. Catecholamine metabolism and in vitro induction of premature cuticle melanization in wild type and pigmentation mutants of Drosophila melanogaster. Arch. Insect. Biochem. Physiol., 1996, 31(2), 219-233.
10. Van Gelder, C.W.; Flurkey, W.H.; Wichers, H.J. Sequence and structural features of plants and fungal tyrosinases. Phytochemistry, 1997, 45, 1309-1323.
11. Halaouli, S.; Asther, M.; Sigoillot, J.C.; Hamdi, M.; Lomascolo, A. Fungal trustiness: new prospects in molecular characteristics, bioengineering and biotechnological applications. J. Appl. Microbiol., 2006, 100(2), 219-232.
12. Gama Sosa, M.A.; De Gasperi, R.; Elder, G.A. Modelling human neurodegenerative diseases in transgenic systems. Hum. Genet., 2012, 131(4), 535-563.
13. Sotnikova, T.D.; Beaulieu, J.M.; Barak, L.S.; Wetsel, W.C.; Caron, M.G.; Gainetdinov, R.R. Dopamine independent locomotor actions of amphetamines in novel acute mouse model of Parkinson Disease. PLoS Biol., 2005, 3(8), e271
14. Mulcahy, P.; O'Doherty, A.; Paucard, A.; O'Brien, T.; Kirik, D.; Dowd, E. Development and characterization of a novel rat model of Parkinson's disease induced by sequential intramural administration of AAV-synuclein and the pesticide, rotenone. Neuroscience, 2012, 203, 170-179.
15. Hirth, F. Drosophila melanogaster in the study of human neurodegeneration. CNS Neurol. Disord. Drug Targets, 2010, 9(4), 504-523.
16. Muqit, M.M.; Feany, M.B. Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat. Rev. Neurosci., 2002, 3(3), 237-243.
17. Calahorro, F.; Ruiz-Rubio, M. Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder. Invert. Neurosci., 2011, 1(2), 73-83.
18. Nass, R.; Merchant, K.M.; Ryan, T. Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need. Mol. Interv., 2008, 8(6), 284-293.
19. Nass, R.; Hall, D.H.; Miller, D.M.; Blakely, R.D. Neurotoxin induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA, 2002, 99(5), 3264-3269.
20. Lee, Y.J.; Wang, S.; Slone, SR.; Yacoubian, T.A.; Witt, S.N. Defects in very long chain fatty acid synthesis enhance alphasynuclein toxicity in a yeast model of Parkinson's disease. PLoS One, 2011, 6(1), e15946.
21. Kaletta, T.; Hengartner, M.O. Finding function in novel targets: C. elegans as a model organism. Nat. Rev. Drug Discov., 2006, 5(5), 387-398.
22. Brenner, S. The genetics of Caenorhabditis elegans. Genetics, 1974, 77(1), 71-94.
23. Nazir, A.; Sammi, S.R.; Singh, P.; Tripathi, R.K. Trans-cellular introduction of HIV-1 protein Nef induces pathogenic response in Caenorhabditis elegans. PLoS One, 2010, 5(12), e15312.
24. Jadiya, P.; Chatterjee, M.; Sammi, S.R.; Kaur, S.; Palit, G.; Nazir A. Sir-2.1 modulates 'calorie-restriction-mediated' prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease. Biochem. Biophys. Res. Commun., 2011, 413(2), 306-310.
25. Stiernagle, T. Maintenance of C. elegans. Worm Book, 2006, 1-11.
26. Simmer, F.; Moorman, C.; van der Linden, A.M.; Kuijk, E.; van den Berghe, P.V.; Kamath, R.S.; Fraser, A.G.; Ahringer, J.; Plasterk, R.H. Genome-wide RNAi of C. elegans using the hypersensitive rrf-3 strain reveals novel gene functions. PLoS Biol., 2003, 1(1), E12.
27. Jadiya, P.; Khan, A.; Sammi, S.R.; Kaur, S.; Mir, S.S.; Nazir, A. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease. Biochem. Biophys. Res. Commun., 2011, 413(4), 605-610.
28. Artal-Sanz, M.; Tavernarakis, N. Prohibitin couples diapause signalling to mitochondrial metabolism during ageing in C. elegans. Nature, 2009, 461(7265), 793-797.
29. Bargmann, C.I.; Hartwieg, E.; Horvitz, H.R. Odorant-selective genes and neurons mediate olfaction in C. elegans. Cell, 1993, 74(3), 515-527.
30. Ashrafi, K.; Chang, F.Y.; Watts, J.L.; Fraser, A.G.; Kamath, R.S.; Ahringer, J.; Ruvkun, G. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature, 2003, 421, 268-272.
31. Mahoney, T.R.; Luo, S.; Nonet, M.L. Analysis of synaptic transmission in Caenorhabditis elegans using an aldicarbsensitivity assay. Nat. Protoc., 2006, 1(4), 1772-1777.
32. Buckingham, SD.; Sattelle, D.B. Fast, automated measurement of nematode swimming (thrashing) without morphometry. BMC Neurosci., 2009, 10, 84.
33. Pu, Pu.; Weidong, Le. Dopamine neuron degeneration induced by MPP+ is independent of CED-4 pathway in Caenorhabditis elegans. Cell Res., 2008, 18, 978-981.
34. Barbagallo, B.; Prescott, H.A.; Boyle, P.; Climer, J.; Francis, M.M. A Dominant Mutation in a Neuronal Acetylcholine Receptor Subunit Leads to Motor Neuron Degeneration in Caenorhabditis elegans. J. Neurosci., 2010, 30(42), 13932-13942.
35. Emerit, I.; Filipe, P.; Freitas, J.; Vassy, J. Protective effect of superoxide dismutase against hair graying in a mouse model. Photochem. Photobiol., 2004, 80(3), 579-582.
36. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388(6645), 839-840.
37. Baptista, M.J.; O'Farrell, C.; Daya, S.; Ahmad, R.; Miller, D.W.; Hardy, J.; Farrer, M.J.; Cookson, M.R. Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J. Neurochem., 2003, 85(4), 957-968.
38. Murata, M. The discovery of an antiparkinsonian drug, zonisamide. Rinsho Shinkeigaku, 2010, 50(11), 780-782.
39. Haavik, J. L-DOPA is a substrate for tyrosine hydroxylase. J. Neurochem., 1997, 69(4), 1720-1728.
40. Schmeisser, S.; Zarse, K.; Ristow, M. Lonidamine extends lifespan of adult Caenorhabditis elegans by increasing the formation of mitochondrial reactive oxygen species. Horm. Metab. Res. 2011, 43(10), 687-692.
41. Bussell, R., Jr.; Eliezer, D. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. Biochemistry, 2004, 43(16), 4810-4818.
42. Kim, J, Poole, D.S.; Waggoner, L.E.; Kempf, A.; Ramirez, D.S.; Treschow, P.A.; Schafer, W.R. Genes affecting the activity of nicotinic receptors involved in Caenorhabditis elegans egg-laying behavior. Genetics, 2001, 157(4), 1599-1610
43. White, J.G.; Southgate, E.; Thomson, J. N.; Brenner, S. The structure of the nervous system of the nematode Caenorhabditis elegans. Phil. Trans. R Soc., Lond. B, 1986, 314 1-340.
44. nd ed.; Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 1997, vol. 314, pp. 1049-1052.
45. Jospin, M.; Qi, Y.B.; Stawicki, T.M.; Boulin, T.; Schuske, K.R.; Horvitz, H.R.; Bessereau, J.L.; Jorgensen, E.M.; Jin, Y.A neuronal acetylcholine receptor regulates the balance of muscle excitation and inhibition in Caenorhabditis elegans. PLoS Biol., 2009, 7(12), e1000265.
46. Sawin, E.R.; Ranganathan, R.; Horvitz, H.R. Celegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron, 2000, 26(3), 619-631.